Regulatory Work to Secure Licence Variation for anastrozole

This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.

Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome

Closing date for submissions is 7th February 2022 at 13:00